Total Funding
56
37
Total FundingPost-IPO Equity raised
Growth Score
-5 pts
Heat Score
-13 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
161898
DURECT is a specialty pharmaceutical company developing innovative drugs for pain and chronic diseases, with late-stage development
James E. Brown: Co-Founder ,President & Chief Executive Officer
Felix Theeuwes: Chairman & Chief Scientific Officer
About the Company
DURECT is a specialty pharmaceutical company developing innovative drugs for pain and chronic diseases, with late-stage development programs including REMOXY®, POSIDUR™, ELADUR®, and TRANSDUR®-Sufentanil. DURECT’s proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial
attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs
